KRTL Holding Announces Acquisition of Neurogen Brain Balancing, LLC – A Strategic Merger Accelerating Global Neurotech and Mental Wellness Expansion
KRTL Holding Group has announced the acquisition of Neurogen Brain Balancing, a California-based neurotechnology company specializing in brain balancing therapies and cognitive optimization systems. The acquisition involves KRTL obtaining 100% of Neurogen's equity through a stock-based structure with a profit-sharing agreement.
The deal positions Neurogen as a KRTL subsidiary, integrating advanced neurotechnology into KRTL's ecosystem. Neurogen's technology offers non-opioid, non-invasive treatment options for cognitive enhancement, stress reduction, and post-trauma recovery. The integration process includes brand alignment, financial system harmonization, and operational planning, supported by KRTL's Quality Management System and Enterprise Resource Planning infrastructure.
As part of the strategic integration, Neurogen will participate in real-world data research through connection with Centro de Investigaciones Químicas - CIQ S.R.L in Bolivia, contributing to global product validation efforts.
KRTL Holding Group ha annunciato l'acquisizione di Neurogen Brain Balancing, un'azienda di neurotecnologia con sede in California specializzata in terapie di bilanciamento cerebrale e sistemi di ottimizzazione cognitiva. L'acquisizione prevede che KRTL ottenga il 100% del capitale di Neurogen attraverso una struttura basata su azioni con un accordo di condivisione dei profitti.
Questo accordo posiziona Neurogen come una sussidiaria di KRTL, integrando tecnologie neuro avanzate nell'ecosistema di KRTL. La tecnologia di Neurogen offre opzioni di trattamento non oppioidi e non invasive per il miglioramento cognitivo, la riduzione dello stress e il recupero post-trauma. Il processo di integrazione include l'allineamento del marchio, l'armonizzazione dei sistemi finanziari e la pianificazione operativa, supportati dal Sistema di Gestione della Qualità di KRTL e dall'infrastruttura di Pianificazione delle Risorse Aziendali.
Come parte dell'integrazione strategica, Neurogen parteciperà alla ricerca di dati reali attraverso una connessione con il Centro de Investigaciones Químicas - CIQ S.R.L in Bolivia, contribuendo agli sforzi di validazione globale del prodotto.
KRTL Holding Group ha anunciado la adquisición de Neurogen Brain Balancing, una empresa de neurotecnología con sede en California que se especializa en terapias de equilibrio cerebral y sistemas de optimización cognitiva. La adquisición implica que KRTL obtenga el 100% del capital de Neurogen a través de una estructura basada en acciones con un acuerdo de participación en las ganancias.
Este acuerdo posiciona a Neurogen como una subsidiaria de KRTL, integrando tecnología neuro avanzada en el ecosistema de KRTL. La tecnología de Neurogen ofrece opciones de tratamiento no opioides y no invasivas para la mejora cognitiva, la reducción del estrés y la recuperación post-trauma. El proceso de integración incluye la alineación de la marca, la armonización de sistemas financieros y la planificación operativa, respaldados por el Sistema de Gestión de Calidad de KRTL y la infraestructura de Planificación de Recursos Empresariales.
Como parte de la integración estratégica, Neurogen participará en la investigación de datos del mundo real a través de la conexión con el Centro de Investigaciones Químicas - CIQ S.R.L en Bolivia, contribuyendo a los esfuerzos de validación de productos a nivel global.
KRTL 홀딩 그룹은 캘리포니아에 본사를 둔 신경 기술 회사인 Neurogen Brain Balancing의 인수를 발표했습니다. 이 회사는 뇌 균형 요법과 인지 최적화 시스템을 전문으로 합니다. 이번 인수로 KRTL은 주식 기반 구조를 통해 Neurogen의 100% 지분을 확보하게 됩니다.
이번 거래는 Neurogen을 KRTL의 자회사로 위치시키며, KRTL의 생태계에 첨단 신경 기술을 통합합니다. Neurogen의 기술은 인지 향상, 스트레스 감소 및 외상 후 회복을 위한 비오피오이드 비침습적 치료 옵션을 제공합니다. 통합 과정에는 브랜드 정렬, 재무 시스템 조화 및 운영 계획이 포함되며, KRTL의 품질 관리 시스템과 기업 자원 계획 인프라에 의해 지원됩니다.
전략적 통합의 일환으로 Neurogen은 볼리비아의 Centro de Investigaciones Químicas - CIQ S.R.L와 연결되어 실제 데이터 연구에 참여하여 글로벌 제품 검증 노력에 기여할 것입니다.
KRTL Holding Group a annoncé l'acquisition de Neurogen Brain Balancing, une entreprise de neurotechnologie basée en Californie spécialisée dans les thérapies d'équilibre cérébral et les systèmes d'optimisation cognitive. L'acquisition implique que KRTL obtienne 100 % des actions de Neurogen par le biais d'une structure basée sur des actions avec un accord de partage des bénéfices.
Cette opération positionne Neurogen en tant que filiale de KRTL, intégrant une technologie neuro avancée dans l'écosystème de KRTL. La technologie de Neurogen offre des options de traitement non opioïdes et non invasives pour l'amélioration cognitive, la réduction du stress et la récupération post-traumatique. Le processus d'intégration comprend l'alignement des marques, l'harmonisation des systèmes financiers et la planification opérationnelle, soutenus par le Système de Gestion de la Qualité de KRTL et l'infrastructure de Planification des Ressources de l'Entreprise.
Dans le cadre de l'intégration stratégique, Neurogen participera à la recherche de données du monde réel grâce à une connexion avec le Centro de Investigaciones Químicas - CIQ S.R.L en Bolivie, contribuant aux efforts de validation des produits à l'échelle mondiale.
KRTL Holding Group hat die Übernahme von Neurogen Brain Balancing angekündigt, einem in Kalifornien ansässigen Neurotechnologieunternehmen, das sich auf Therapien zur Gehirnbalancierung und kognitive Optimierungssysteme spezialisiert hat. Die Übernahme beinhaltet, dass KRTL 100 % des Eigenkapitals von Neurogen durch eine aktienbasierte Struktur mit einer Gewinnbeteiligungsvereinbarung erwirbt.
Das Geschäft positioniert Neurogen als Tochtergesellschaft von KRTL und integriert fortschrittliche Neurotechnologie in das Ökosystem von KRTL. Die Technologie von Neurogen bietet nicht-opioide, nicht-invasive Behandlungsoptionen zur kognitiven Verbesserung, Stressreduktion und posttraumatischen Erholung. Der Integrationsprozess umfasst die Markenanpassung, die Harmonisierung der Finanzsysteme und die operative Planung, unterstützt durch das Qualitätsmanagementsystem von KRTL und die Infrastruktur der Unternehmensressourcenplanung.
Im Rahmen der strategischen Integration wird Neurogen an der Forschung zu realen Daten durch die Verbindung mit dem Centro de Investigaciones Químicas - CIQ S.R.L in Bolivien teilnehmen und zur globalen Produktvalidierung beitragen.
- Strategic acquisition expands KRTL's presence in mental wellness and neurotechnology markets
- 100% equity acquisition provides full control over Neurogen's innovative technology
- Integration with KRTL's regulatory infrastructure enhances FDA compliance and market access
- Access to global research capabilities through CIQ S.R.L partnership in Bolivia
- Stock-based acquisition structure may lead to shareholder dilution
- Integration costs and operational alignment may impact short-term financial performance
- No disclosed financial terms or valuation of the acquisition
Lakewood, CO, April 09, 2025 (GLOBE NEWSWIRE) -- FOR IMMEDIATE RELEASE
KRTL Holding Announces Acquisition of Neurogen Brain Balancing, LLC – A Strategic Merger Accelerating Global Neurotech and Mental Wellness Expansion
KRTL Holding Group Inc., a diversified international enterprise focused on biotech innovation, regulatory infrastructure, and strategic investment, is pleased to announce the acquisition of Neurogen Brain Balancing, LLC, a California-based neurotechnology company known for its advanced brain balancing therapies and personalized cognitive optimization systems. This transformative acquisition expands KRTL’s presence in the mental wellness space and enhances its position at the intersection of neuroscience, biotechnology, and global healthcare.
This acquisition establishes Neurogen as a subsidiary of KRTL Holding Group Inc., representing a pivotal step in the company’s broader strategy to integrate advanced neurotechnology into its ecosystem and support the growth of scalable mental health solutions.
Under the terms of the transaction, KRTL has acquired
“We are thrilled to welcome Neurogen into the KRTL Holding Group family,” said Cesar Herrera, CEO of KRTL Holding Group. “In today’s rapidly evolving global environment, diversification is not just a strategy—it’s a necessity. By bringing Neurogen into our ecosystem, we strengthen our ability to remain agile, resilient, and forward-thinking across multiple sectors. Their innovative work is a natural fit for our mission to invest in businesses that shape the future.”
Neurogen’s proprietary neurotechnology utilizes advanced neuromodulation protocols that support applications ranging from cognitive performance enhancement to stress reduction and post-trauma recovery. The platform is particularly well-positioned to address critical gaps in the continuation of care for patients seeking alternative therapies. By offering non-opioid, non-invasive treatment options with simplified access, the technology aligns with broader healthcare priorities around expanding safe, effective, and accessible behavioral and neurological health interventions.
"This acquisition marks an exciting new chapter for Neurogen. Joining forces with KRTL Holding Group enables us to accelerate our mission of transforming mental health treatment through cutting-edge neurotechnology. With KRTL’s global infrastructure and regulatory expertise, we’re well-positioned to scale our solutions and reach underserved communities worldwide. Together, we aim to expand access to non-invasive, personalized brain health therapies—advancing a new global standard for neurological wellness," said Gregory Gillispie, President of NeuroGen. "The guidance and infrastructure offered by KRTL enhance our ability to grow responsibly while continuing to focus on improving lives through brain balance."
Strategic Integration and Global Expansion Framework
As part of the integration, Neurogen is being incorporated into KRTL’s operational and regulatory infrastructure. These efforts, which include brand alignment across digital channels and investor communications, financial system harmonization, and scalable operational planning, are underway and being informed by both internal leadership and third-party advisors.
KRTL’s internal systems, including its Quality Management System (QMS) and Enterprise Resource Planning (ERP) infrastructure, are currently under expert review. This assessment is aimed at identifying the most effective enhancements to support joint business capabilities and long-term performance.
Further coordination is focused on regulatory and clinical alignment, including FDA-compliant trial design and support for international submissions. Neurogen is also positioned to participate in real-world data research through its connection with Centro de Investigaciones Químicas - CIQ S.R.L in Bolivia, contributing to global product validation efforts.
As the collaboration evolves, KRTL intends to issue follow-up announcements that will provide added clarity, updates on integration progress, and forward-looking insights.
About KRTL Holding Group Inc.
KRTL Holding Group Inc. is a dynamic holding company operating through its wholly owned subsidiaries, KRTL Biotech, Inc. and KRTL International Corp. These subsidiaries specialize in biopharmaceutical innovation, international trade, and compliance-driven healthcare advancements. By leveraging strategic mergers, acquisitions, and joint ventures, KRTL Holding Group continues to push the boundaries of scientific research, regulatory compliance, and global business solutions.
Additional information on KRTL is available online at www.krtlholding.com and www.krtl-icc.com and www.krtlbiotech.com.
This press release contains forward-looking statements under the meaning of the Private Securities Litigation Reform Act of 1995. These statements include, but are not limited to, anticipated business developments, regulatory advancements, and strategic growth plans. Such forward-looking statements involve known and unknown risks that may cause actual results to differ materially from those expressed or implied.
KRTL Holding Group assumes no obligation to update or revise forward-looking statements, except as required by law. Any updates will be made in accordance with applicable SEC regulations and disclosure obligations. Readers are cautioned not to place undue reliance on forward-looking statements.
www.krtlholding.com info@krtlholding.com www.krtlbiotech.com info@krtlbiotech.com www.krtl-icc.com info@krtl-icc.com
FAQ
What are the key terms of KRTL's acquisition of Neurogen Brain Balancing?
How will Neurogen's technology benefit KRTL's healthcare portfolio?
What integration steps is KRTL implementing for Neurogen in 2025?
How will KRTL expand Neurogen's global reach?
